Powering Vaccine R&D: A Discussion on the Future of the Global Ecosystem for Vaccine R&D
The rapid development of COVID-19 vaccines is fueling a reimagining of what is possible for vaccine research and development (R&D). Join us for a panel discussion and Q&A reflecting on ideas offered in a forthcoming report by the Sabin-Aspen Vaccine Science & Policy Group, Powering Vaccine R&D: Opportunities for Transformation. This report will draw on historic lessons learned from vaccine development to outline opportunities to overhaul vaccine R&D practices to better prepare for the next pandemic, to make strides against diseases currently without vaccines, and to establish next-generation vaccines that offer meaningful improvements. Expert panelists will reflect on what it will take to transform the vaccine R&D ecosystem and how stakeholders at all levels can help support those efforts.
FEATURING:
Brief overview of report by Dr. Bruce Gellin, President of Global Immunization, Sabin Vaccine Institute; member, Sabin-Aspen Vaccine Science & Policy Group
Panel discussion moderated by Jamie Bay Nishi, Director, Global Health Technologies Coalition (GHTC), featuring:
- Dr. Kundai Chinyenze, Executive Medical Director, IAVI, Uganda
- Dr. Penny Heaton, Chief Executive Officer, Bill & Melinda Gates Medical Research Institute; member, Sabin-Aspen Vaccine Science & Policy Group
- Dr. John Nkengasong, Director, Africa Centres for Disease Control and Prevention
- Prof. Helen Rees, Executive Director, Wits Reproductive Health and HIV Institute, University of the Witwatersrand; member, Sabin-Aspen Vaccine Science & Policy Group
